|
DE102006042143A1
(de)
*
|
2006-09-08 |
2008-03-27 |
Bayer Healthcare Aktiengesellschaft |
Neue substituierte Bipyridin-Derivate und ihre Verwendung
|
|
DE102006056740A1
(de)
*
|
2006-12-01 |
2008-06-05 |
Bayer Healthcare Ag |
Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
|
|
DE102006056739A1
(de)
*
|
2006-12-01 |
2008-06-05 |
Bayer Healthcare Ag |
Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
|
|
DE102007035367A1
(de)
|
2007-07-27 |
2009-01-29 |
Bayer Healthcare Ag |
Substituierte Aryloxazole und ihre Verwendung
|
|
DE102007036076A1
(de)
|
2007-08-01 |
2009-02-05 |
Bayer Healthcare Aktiengesellschaft |
Dipeptoid-Produgs und ihre Verwendung
|
|
DE102007061763A1
(de)
*
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Substituierte azabicyclische Verbindungen und ihre Verwendung
|
|
DE102007061764A1
(de)
*
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Anellierte Cyanopyridine und ihre Verwendung
|
|
US8343966B2
(en)
*
|
2008-01-11 |
2013-01-01 |
Novartis Ag |
Organic compounds
|
|
DE102008013587A1
(de)
*
|
2008-03-11 |
2009-09-17 |
Bayer Schering Pharma Aktiengesellschaft |
Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
|
|
CA2726020C
(en)
*
|
2008-05-29 |
2016-08-16 |
Bayer Schering Pharma Aktiengesellschaft |
2-alkoxy-substituted dicyanopyridines and use thereof
|
|
TW201028381A
(en)
*
|
2008-07-14 |
2010-08-01 |
Shionogi & Co |
Pyridine derivative having ttk inhibition activity
|
|
DE102008062567A1
(de)
|
2008-12-16 |
2010-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Dipeptoid-Prodrugs und ihre Verwendung
|
|
DE102009006602A1
(de)
*
|
2009-01-29 |
2010-08-05 |
Bayer Schering Pharma Aktiengesellschaft |
Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
|
|
EP2440204B1
(en)
|
2009-06-12 |
2013-12-18 |
Bristol-Myers Squibb Company |
Nicotinamide compounds useful as kinase modulators
|
|
JP2013525367A
(ja)
|
2010-04-23 |
2013-06-20 |
キネタ・インコーポレイテツド |
抗ウイルス性化合物
|
|
NZ603789A
(en)
*
|
2010-05-26 |
2015-03-27 |
Sunovion Pharmaceuticals Inc |
Heteroaryl compounds and methods of use thereof
|
|
DE102010030688A1
(de)
|
2010-06-30 |
2012-01-05 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte Dicyanopyridine und ihre Verwendung
|
|
US20120058983A1
(en)
|
2010-09-02 |
2012-03-08 |
Bayer Pharma Aktiengesellschaft |
Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
|
|
MX2015002555A
(es)
*
|
2012-08-30 |
2015-06-23 |
Nippon Shinyaku Co Ltd |
Derivado de piridina y medicina.
|
|
SG11201509186TA
(en)
|
2013-06-27 |
2016-01-28 |
Pfizer |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
|
EP3116513A4
(en)
*
|
2014-03-14 |
2017-10-25 |
Andes Biotechnologies S.A. |
Pharmaceutical compositions comprising rna and use for treating cancer
|
|
GB201514021D0
(en)
|
2015-08-07 |
2015-09-23 |
Arner Elias Set Jeno |
Novel Pyridines and their use in the treatment of cancer
|
|
US11168068B2
(en)
|
2016-07-18 |
2021-11-09 |
Janssen Pharmaceutica Nv |
Tau PET imaging ligands
|
|
MA47450A
(fr)
|
2017-02-07 |
2019-12-18 |
Oblique Therapeutics Ab |
Sulfinylpyridines et leur utilisation dans le traitement du cancer
|
|
CA3051539A1
(en)
|
2017-02-07 |
2018-08-16 |
Oblique Therapeutics Ab |
Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer
|
|
US11168069B2
(en)
|
2017-02-07 |
2021-11-09 |
Oblique Therapeutics Ab |
Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
|
|
AU2018218519B2
(en)
|
2017-02-07 |
2021-08-05 |
Oblique Therapeutics Ab |
Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
|